ABVC BioPharma (ABVC) vs Evaxion A/S (EVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evaxion A/S (EVAX) has outperformed ABVC BioPharma (ABVC) over the past year, losing 51.5% versus a loss of 69.8%. Over five years, ABVC leads with a -96.4% price change compared with -99.2% for EVAX. Evaxion A/S is the larger company by market cap ($27.5 million vs $26.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | EVAX |
|---|---|---|
| Share price | $0.98 | $3.05 |
| Market cap | $26.16M | $27.52M |
| 1-day change | -2.00% | -2.87% |
| YTD return | -53.99% | -36.06% |
| 1-year return | -69.75% | -51.51% |
| 5-year return | -96.38% | -99.23% |
| EPS (TTM) | $-0.30 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.33 | $12.15 |
| 52-week low | $0.707 | $2.77 |
| Distance from 52-week high | -70.54% | -74.90% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +268.85% |
| Average volume | 111.36K | 200.14K |
| Shares outstanding | 26.69M | 9.02M |
| Employees | 16 | 46 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed ABVC by 18.2 percentage points over the past year.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Healthcare · Biotechnology · 16 employees
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
ABVC vs EVAX FAQ
Which is bigger, ABVC BioPharma or Evaxion A/S?
Evaxion A/S (EVAX) is larger, with a market capitalization of $27.52M compared with $26.16M for ABVC BioPharma (ABVC).
Which stock has performed better over the past year, ABVC or EVAX?
EVAX returned -51.51% over the past 12 months, compared with -69.75% for ABVC (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and Evaxion A/S in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.